Collaborating transatlantically are UK based Center for Clinical Brain Sciences established as recently as 2004 and USA based Biogen. A landmark clinical study will observe three licensed drugs for neurological conditions. Late stage progressive form of multiple sclerosis (MS) patients will be monitored for two years says Prof. Siddharthan Chandran, Director of the Anne Rowling Clinic. MRI scans will test for signs of MS disease progression. The research initiative is being funded by Biogen. The UK researchers will provide greater insight into the cell and biological processes behind progressive neurological diseases.
Over 35 million people are affected and the global cost for treatment and care is at 700 billion and rising. Multiple sclerosis progresses fast. Within 18 months of the first symptoms a person may become wheel chair bound. How does the brain cell wiring system get damaged so rapidly? The hope lies in a new discovery – stem cells can spontaneously repair damaged brain cells, by laying new myelin over nerve cells. Treatment options being considered for research are by either activating existing stem cells in the brain or by transplanting stem cells to replace dead or dying brain cells. The UK research team has done the ground work for this research since their public is open to the advantages of stem cell research and understand the implications of using a patient’s own stem cells. This risky and super expensive research needs visionary and patient funding leaders. That is where Biogen comes in. Naturally, such collaborations cannot be done in countries where the citizens do not understand or are opposed to the possibilities of stem cell research.
Dr. Siddharthan Chandran gave a talk at TEDGlobal 2013 describing his vision of hope for neurodegenerative diseases of the brain. See a description of his talk and more images by clicking here or at: http://blog.ted.com/2013/06/12/regenerating-hope-tedglobal-2013-with-siddharthan-chandran/